Data Presented at AACR Meeting Show Peregrine's Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer

Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, announced preclinical studies presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that 2aG4, a mouse equivalent to the company's anti-phosphatidylserine (PS) antibody bavituximab has vaccine- like activity and can generate curative responses in an aggressive model of brain cancer. Researchers also presented data demonstrating that this improvement in survival was likely attributable to the ability of 2aG4 to enable the treated animals to...

Want to see the full article?

• Purchase this article for only $3.00